PDF(Pubmed)
Abstract：
OBJECTIVE: To investigate the various strategies used for the treatment of premature ejaculation (PE); these encompassed behavioral, drug and surgical interventions.
METHODS: We retrieved data from electronic literature searches of PubMed and Cochrane library using the MeSH (Medical Subject Headings terms) and text keywords from the earliest available date of indexing through September 2022. The subject headings and text keywords included those related to the population (male patients with PE), interventions & comparisons (mono and combination treatment), and outcomes (ejaculation latency time, ELT).
RESULTS: The initial search identified a total of 454 articles from electronic databases. Finally, a total of 10,474 patients from 59 direct comparison trials were included 143 effect sizes with 43 treatments. Of these, 9 of mono treatments and 4 of combination treatments were statistically significant. Pharmaceutical agents commonly used for patients with PE are prescribed off-label, except for dapoxetine. The surface under the cumulative ranking curve values of ranking probabilities for each treatment performance, which indicated that tramadol 100 mg ranked first in terms of ELT.
CONCLUSIONS: Medications recommended by the American Urological Association and the Sexual Medicine Society of North America were all incorporated within the present review, together with additional management approaches that have been evaluated in randomized controlled trials. The findings indicated that in addition to SSRIs, tramadol, clomipramine, topical agents and PDE5 inhibitors could be used in the therapy of PE.
METHODS: We retrieved data from electronic literature searches of PubMed and Cochrane library using the MeSH (Medical Subject Headings terms) and text keywords from the earliest available date of indexing through September 2022. The subject headings and text keywords included those related to the population (male patients with PE), interventions & comparisons (mono and combination treatment), and outcomes (ejaculation latency time, ELT).
RESULTS: The initial search identified a total of 454 articles from electronic databases. Finally, a total of 10,474 patients from 59 direct comparison trials were included 143 effect sizes with 43 treatments. Of these, 9 of mono treatments and 4 of combination treatments were statistically significant. Pharmaceutical agents commonly used for patients with PE are prescribed off-label, except for dapoxetine. The surface under the cumulative ranking curve values of ranking probabilities for each treatment performance, which indicated that tramadol 100 mg ranked first in terms of ELT.
CONCLUSIONS: Medications recommended by the American Urological Association and the Sexual Medicine Society of North America were all incorporated within the present review, together with additional management approaches that have been evaluated in randomized controlled trials. The findings indicated that in addition to SSRIs, tramadol, clomipramine, topical agents and PDE5 inhibitors could be used in the therapy of PE.
摘要：
目的：研究治疗早泄（PE）的各种策略；这些策略包括行为，药物和手术干预。
方法：我们使用MeSH（医学主题词）和文本关键词从PubMed和Cochrane图书馆的电子文献检索中检索到了数据，这些数据从最早的索引日期到2022年9月。主题词和文本关键词包括与人群相关的关键词（男性PE患者），干预措施和比较(单一和联合治疗)，和结果(射精潜伏期，ELT)。
结果：最初的搜索从电子数据库中确定了总共454篇文章。最后,来自59项直接比较试验的10,474例患者共纳入43种治疗方法的143种效应大小.其中,9种单一治疗和4种组合治疗在统计学上是显著的。通常用于PE患者的药物是处方外的，除了达泊西汀.每种处理性能的排名概率的累积排名曲线值之下的表面，这表明曲马多100mg在ELT方面排名第一。
结论：美国泌尿外科协会和北美性医学协会推荐的药物均纳入本综述，以及在随机对照试验中评估的其他管理方法.研究结果表明，除了SSRIs，曲马多,氯米帕明,外用药物和PDE5抑制剂可用于PE的治疗.
方法：我们使用MeSH（医学主题词）和文本关键词从PubMed和Cochrane图书馆的电子文献检索中检索到了数据，这些数据从最早的索引日期到2022年9月。主题词和文本关键词包括与人群相关的关键词（男性PE患者），干预措施和比较(单一和联合治疗)，和结果(射精潜伏期，ELT)。
结果：最初的搜索从电子数据库中确定了总共454篇文章。最后,来自59项直接比较试验的10,474例患者共纳入43种治疗方法的143种效应大小.其中,9种单一治疗和4种组合治疗在统计学上是显著的。通常用于PE患者的药物是处方外的，除了达泊西汀.每种处理性能的排名概率的累积排名曲线值之下的表面，这表明曲马多100mg在ELT方面排名第一。
结论：美国泌尿外科协会和北美性医学协会推荐的药物均纳入本综述，以及在随机对照试验中评估的其他管理方法.研究结果表明，除了SSRIs，曲马多,氯米帕明,外用药物和PDE5抑制剂可用于PE的治疗.
